# Perceptive Advisors LLC 13F holdings Q2 2026: $6.7 billion

Perceptive Advisors LLC reported $6.7 billion in 13F securities across 109 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Praxis Precision Medicines I at $682 million, 10.2% of the reported value. Since Q1 2026 it opened 29 new positions and exited 14.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $6,661,817,069
- Positions: 109
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1224962
- Form 13F file number: 028-10438
- CRD number: 154703
- Business address: 51 Astor Place, 10th Floor, New York, NY 10003
- SEC filing: [0001012975-26-000777](https://www.sec.gov/Archives/edgar/data/1224962/000101297526000777/0001012975-26-000777-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/perceptive-advisors-154703)

## Top 25 holdings by value

The largest of 109 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 2,035,986 | $681.6 million | No change |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 4,319,496 | $383.5 million | +536,271 |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102k100) | COM | 3,197,200 | $334.5 million | +70,000 |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 1,163,721 | $310.4 million | New |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 2,586,295 | $287.2 million | +212,500 |
| [Roivant Sciences LTD](https://specstream.ai/data/institutional-holders/roivant-sciences-ltd-g76279101) | SHS | 8,085,461 | $286.1 million | -200,000 |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 14,106,187 | $263.9 million | +4,355,046 |
| [Travere Therapeutics Inc](https://specstream.ai/data/institutional-holders/travere-therapeutics-inc-89422g107) | COM | 3,752,574 | $213.2 million | -389,977 |
| [Kardigan Inc](https://specstream.ai/data/institutional-holders/kardigan-inc-485925101) | COM | 8,200,662 | $195.6 million | New |
| [Nuvalent Inc](https://specstream.ai/data/institutional-holders/nuvalent-inc-670703107) | COM | 1,580,505 | $195.2 million | No change |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 4,373,974 | $177.7 million | -50,000 |
| [Apogee Therapeutics Inc](https://specstream.ai/data/institutional-holders/apogee-therapeutics-inc-03770n101) | COM | 1,308,113 | $173.6 million | -232,271 |
| [Amylyx Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/amylyx-pharmaceuticals-inc-03237h101) | COM | 8,334,882 | $149.7 million | +50,000 |
| [Meiragtx Hldgs PLC](https://specstream.ai/data/institutional-holders/meiragtx-hldgs-plc-g59665102) | COM | 10,786,658 | $145.7 million | +460,555 |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 1,345,063 | $128 million | -50,438 |
| [Inhibrx Biosciences Inc](https://specstream.ai/data/institutional-holders/inhibrx-biosciences-inc-45720n103) | COM | 1,297,763 | $123 million | -144,944 |
| [Protagonist Therapeutics Inc](https://specstream.ai/data/institutional-holders/protagonist-therapeutics-inc-74366e102) | COM | 981,879 | $120.4 million | -249,000 |
| [Solid Biosciences Inc](https://specstream.ai/data/institutional-holders/solid-biosciences-inc-83422e204) | COM NEW | 11,906,646 | $118.9 million | No change |
| [Zymeworks Inc](https://specstream.ai/data/institutional-holders/zymeworks-inc-98985y108) | COM | 4,182,953 | $109.3 million | +672,875 |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 3,377,000 | $105.6 million | +2,568,847 |
| [Immatics N.V](https://specstream.ai/data/institutional-holders/immatics-n-v-n44445109) | SHS | 10,383,456 | $105.2 million | No change |
| [Nurix Therapeutics Inc](https://specstream.ai/data/institutional-holders/nurix-therapeutics-inc-67080m103) | COM | 4,320,422 | $104.8 million | +609,545 |
| [Biocryst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/biocryst-pharmaceuticals-inc-09058v103) | COM | 10,308,888 | $103.1 million | +2,874,855 |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 527,600 | $98.8 million | +269,000 |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 2,675,296 | $88.1 million | New |

## New positions in Q2 2026

29 positions not in the filing for the quarter ended March 31, 2026. The 25 largest are shown.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 1,163,721 | $310.4 million |
| [Kardigan Inc](https://specstream.ai/data/institutional-holders/kardigan-inc-485925101) | COM | 8,200,662 | $195.6 million |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 2,675,296 | $88.1 million |
| [Biogen Inc](https://specstream.ai/data/institutional-holders/biogen-inc-09062x103) | COM | 276,173 | $59.7 million |
| [Unitedhealth Group Inc](https://specstream.ai/data/institutional-holders/unitedhealth-group-inc-91324p102) | COM | 116,806 | $48.5 million |
| SPDR Series Trust | ST STR SP BIOT (put) | 300,000 | $47.5 million |
| [Charles Riv Labs Intl Inc](https://specstream.ai/data/institutional-holders/charles-riv-labs-intl-inc-159864107) | COM | 140,000 | $31.8 million |
| Eyepoint Inc | COM NEW (put) | 2,000,000 | $28.6 million |
| [Danaher Corp Del](https://specstream.ai/data/institutional-holders/danaher-corp-del-235851102) | COM | 130,000 | $24.8 million |
| Capricor Therapeutics Inc | COM NEW (call) | 1,000,000 | $24.1 million |
| Sellas Life Sciences Group I | COM NEW (put) | 1,500,000 | $22.1 million |
| [Adlai Nortye LTD](https://specstream.ai/data/institutional-holders/adlai-nortye-ltd-00704r109) | SPONSORED ADS | 1,793,190 | $20.6 million |
| [Nuvectis Pharma Inc](https://specstream.ai/data/institutional-holders/nuvectis-pharma-inc-67080t108) | COM | 1,000,000 | $18.4 million |
| Newamsterdam Pharma Company | ORDINARY SHARES (put) | 500,000 | $16.9 million |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 115,391 | $13.5 million |
| Capricor Therapeutics Inc | COM NEW (put) | 500,000 | $12 million |
| [Oscar Health Inc](https://specstream.ai/data/institutional-holders/oscar-health-inc-687793109) | CL A | 400,000 | $11.4 million |
| [Seaport Therapeutics Inc](https://specstream.ai/data/institutional-holders/seaport-therapeutics-inc-81221k108) | COMMON STOCK | 500,000 | $10.9 million |
| [Boston Scientific Corp](https://specstream.ai/data/institutional-holders/boston-scientific-corp-101137107) | COM | 250,000 | $10.7 million |
| [Natera Inc](https://specstream.ai/data/institutional-holders/natera-inc-632307104) | COM | 34,689 | $9.4 million |
| [Engene Therapeutics Inc](https://specstream.ai/data/institutional-holders/engene-therapeutics-inc-29286x101) | COM | 4,822,169 | $8.3 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 750,000 | $8 million |
| [Cullinan Therapeutics Inc](https://specstream.ai/data/institutional-holders/cullinan-therapeutics-inc-230031106) | COM | 426,478 | $7.8 million |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 168,000 | $7.7 million |
| [Mobia Med Inc](https://specstream.ai/data/institutional-holders/mobia-med-inc-60705v103) | COMMON STOCK | 523,654 | $7 million |

## Positions exited in Q2 2026

14 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Ascendis Pharma A/S | SPONSORED ADR | 1,531,421 | $350.3 million |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 5,258,903 | $208.9 million |
| Engene Holdings Inc | COM | 5,827,506 | $39.7 million |
| Day One Biopharmaceuticals I | COM | 1,755,799 | $37.6 million |
| [Bright Minds Biosciences Inc](https://specstream.ai/data/institutional-holders/bright-minds-biosciences-inc-10919w405) | COM NEW | 377,544 | $27.5 million |
| [Belite Bio Inc](https://specstream.ai/data/institutional-holders/belite-bio-inc-07782b104) | SPONSORED ADS | 151,979 | $24.2 million |
| [Evommune Inc](https://specstream.ai/data/institutional-holders/evommune-inc-30054y107) | COM SHS | 448,350 | $10.3 million |
| [Neumora Therapeutics Inc.](https://specstream.ai/data/institutional-holders/neumora-therapeutics-inc-640979100) | COM | 5,104,097 | $10 million |
| [Neurocrine Biosciences Inc](https://specstream.ai/data/institutional-holders/neurocrine-biosciences-inc-64125c109) | COM | 65,050 | $8.6 million |
| [Opus Genetics Inc](https://specstream.ai/data/institutional-holders/opus-genetics-inc-67577r102) | COM | 1,835,842 | $8.4 million |
| Ocular Therapeutix Inc | COM (call) | 500,000 | $4.2 million |
| [Inhibikase Therapeutics Inc](https://specstream.ai/data/institutional-holders/inhibikase-therapeutics-inc-45719w205) | COM NEW | 2,315,000 | $3.9 million |
| Apellis Pharmaceuticals Inc | COM | 80,956 | $3.3 million |
| [Palatin Technologies Inc](https://specstream.ai/data/institutional-holders/palatin-technologies-inc-696077601) | COM NEW | 61,945 | $1.1 million |

## Also on SpecStream

- [Perceptive Advisors LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1224962/000101297526000777/0001012975-26-000777-index.htm)
- [Perceptive Advisors LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/perceptive-advisors-154703)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Colleges and universities in New York, New York](https://specstream.ai/data/businesses/colleges-and-universities/new-york-new-york-united-states)
- [Middle schools in New York, New York](https://specstream.ai/data/businesses/middle-schools/new-york-new-york-united-states)
- [Asian fusion restaurants in New York, New York](https://specstream.ai/data/businesses/asian-fusion-restaurants/new-york-new-york-united-states)
- [Immigration law firms in New York, New York](https://specstream.ai/data/businesses/immigration-law-firms/new-york-new-york-united-states)
- [Taco restaurants in New York, New York](https://specstream.ai/data/businesses/taco-restaurants/new-york-new-york-united-states)
- [Electronic equipment suppliers in New York, New York](https://specstream.ai/data/businesses/electronic-equipment-suppliers/new-york-new-york-united-states)
